Dr. Sharad Kumar Jain, MD

Dr. Jain practices at Texas Oncology PA in Denton, Texas.

Dr. Jain's NPI, 1467494385, was assigned on June 12, 2006. Dr. Jain graduated from Maulana Azad Medical College in 1981. Dr. Jain holds Texas license L2348.

Dr. Jain's primary practice is Texas Oncology PA, at 2600 Scripture St, Denton, TX 76201 in Denton County. The practice phone is (972) 997-8000.

Dr. Jain's primary practice is Texas Oncology PA in Denton, Texas. Dr. Jain is also affiliated with Medical City Denton. The medical group on file is Texas Oncology. Dmand AI also links Dr. Jain to 5 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jain practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Jain's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Jain is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Jain's licenses on file in 3 states: Texas, Arizona and Pennsylvania.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Jain treats.

CMS data shows 58,007 Medicare services from Dr. Jain across 55 procedure codes in 2024, for 664 Medicare patients. Medicare paid $305,906 for them.

CMS counts 664 Medicare patients who saw Dr. Jain in 2024. The largest group is 75 to 84, with 299 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.95, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jain's median patient age at 73, with 62% women.

In 2024, Dr. Jain wrote 2,082 Medicare Part D claims for 274 patients. 80% of them were for generic drugs. CMS names the drug for 1,805 of them, across 55 drugs with 11 or more claims each, at $3,719,171 in total drug cost. In 2023, CMS named 1,791 claims across 50 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Jain for performance year 2024, reported through an alternative payment model (APM). Dr. Jain accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Jain as offering telehealth.

Dmand AI links 19 papers to Dr. Jain, published from 2011 to 2025. 2021 was the busiest year, with 4. The most frequent topics are Students, Medical, Persons with Disabilities and Education, Medical, Undergraduate. Dr. Jain has published most often in Acad Med. Dr. Jain's most frequent co-authors are Christopher Jay Moreland, MD, MPH, Rahul G. Patwari, MD and Nancy R. Angoff, MD.

Dmand AI links Dr. Jain to 11 clinical trials, 5 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Breast Neoplasms, Waldenstrom Macroglobulinemia and Breast Diseases. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Jain that name 2 trials.

CMS Open Payments shows 290 general payments to Dr. Jain from 53 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 61% of the total. Kite Pharma, Inc. paid the most, $11,810. It also lists 12 research payments totaling $4,857 from 2018 to 2025, naming 2 clinical trials.

Dmand AI lists 1 award for Dr. Jain, most recently CMS Stage 1 2012 in 2012.

Dr. Jain graduated from Maulana Azad Medical College in 1981.

Dr. Jain is in network with 24 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 15. Check the plan with the practice before a visit.